This post was originally published on this site
Moderna Inc. said Wednesday it has made the initial batch of doses of a new COVID-19 vaccine designed to better protect people against a new strain of the coronavirus that has shown some resistance to the company’s original vaccine.
The Cambridge, Mass., company said it shipped the new shots to the National Institutes of Health to conduct the first human study of the variant vaccine, which could start within weeks.
